Christos Tsoukas

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. ncbi Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy
    Christos Tsoukas
    McGill University Health Centre, Montreal General Hospital, 1650 Cedar Ave, Rm A5 140, Montreal, QC H3G 1A4, Canada
    Blood 107:1785-90. 2006
  2. ncbi Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries
    Janet M Raboud
    Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    BMC Infect Dis 10:40. 2010
  3. ncbi T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers
    Philomena Kamya
    Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    AIDS Res Ther 8:20. 2011
  4. ncbi Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
    Sabine Kinloch-de Loes
    Department of Medicine, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    J Infect Dis 192:607-17. 2005
  5. ncbi Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
  6. ncbi Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008

Collaborators

  • S P Curtis
  • Michael W Dunne
  • Jean Michel Molina
  • Edwin DeJesus
  • R M Gulick
  • Philomena Kamya
  • Pierre Cote
  • Janet M Raboud
  • Benoit Trottier
  • Brian Conway
  • Julio S G Montaner
  • Gerd Fatkenheuer
  • David A Cooper
  • Pierre Marie Girard
  • Manuel Battegay
  • Pierre-Marie Girard
  • Sabine Kinloch-de Loes
  • Colin Kovacs
  • Mohamed Rachid Boulassel
  • RéJean Thomas
  • Salix Boulet
  • Jean Pierre Routy
  • Rupert Kaul
  • Nicole F Bernard
  • Cecile L Tremblay
  • Mario Ostrowski
  • Bernard Lessard
  • Svetlana Draskovic
  • Bruno Lemay
  • Kevin Gough
  • David Milan
  • Nahimi Samia
  • Sharon Walmsley
  • Zoran Stjepanovic
  • Curtis Cooper
  • Viviane Lima
  • Gloria Aykroyd
  • Marina B Klein
  • Hong Yang
  • Sandra Gardner
  • Silvia Guillemi
  • Jeff Cohen
  • Richard Lalonde
  • David Moore
  • David Haase
  • Mona Loutfy
  • Shari Margolese
  • Wendy Wobeser
  • Danielle Rouleau
  • Irving Salit
  • Darien Taylor
  • Mark Fisher
  • Joseph Cox
  • John Cairney
  • Julio Montaner
  • Sherine Sterling
  • Janet Raboud
  • P Richard Harrigan
  • Anita Rachlis
  • Sean Rourke
  • Stanley Read
  • Don Kilby
  • Robert S Hogg
  • Marina Klein
  • Maggie Li
  • Robert Hogg
  • Neora Pick
  • DeSheng Su
  • Sergio Rueda
  • Benita Yip
  • George Hatzakis
  • Marek Smieja
  • Shariq Haider
  • Louise Balfour
  • Sean Hosein
  • Ahmed Bayoumi
  • Anya Shen
  • Evelyne Ssengendo
  • Peggy Millson
  • Ahmed M Bayoumi
  • Roger Sandre
  • Richard Harrigan
  • Mark Tyndall
  • Nada Gataric
  • Ed Mills
  • Marianne Harris
  • Mona R Loutfy
  • Liviana Calzavara
  • Nima Machouf
  • Robert Flisiak

Detail Information

Publications6

  1. ncbi Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy
    Christos Tsoukas
    McGill University Health Centre, Montreal General Hospital, 1650 Cedar Ave, Rm A5 140, Montreal, QC H3G 1A4, Canada
    Blood 107:1785-90. 2006
    ..6%) and during part 2 between etoricoxib (77.0%) and rofecoxib (78.9%). We conclude that etoricoxib provided superior efficacy versus placebo for the treatment of hemophilic arthropathy and was generally safe and well tolerated...
  2. ncbi Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries
    Janet M Raboud
    Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    BMC Infect Dis 10:40. 2010
    ....
  3. ncbi T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers
    Philomena Kamya
    Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    AIDS Res Ther 8:20. 2011
    ..abstract:..
  4. ncbi Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
    Sabine Kinloch-de Loes
    Department of Medicine, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    J Infect Dis 192:607-17. 2005
    ..Our trial design appears to be feasible and safe for testing future immune-boosting strategies...
  5. ncbi Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  6. ncbi Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....